Literature DB >> 23627903

How selective are the new guidelines for treatment of subclinical hypothyroidism for patients with thyrotropin levels at or below 10 mIU/L?

Pedro Weslley Rosario1, Maria Regina Calsolari.   

Abstract

BACKGROUND: By consensus, a thyrotropin (TSH) level persistently >10 mIU/L is an indication for the treatment of subclinical hypothyroidism (SCH). Controversy exists regarding patients whose TSH level is elevated but <10 mIU/L. Recently, the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) published their position about factors that should be considered in the decision on treating SCH. This study evaluated the frequency of these factors among adult (non-pregnant) women with SCH whose TSH levels are ≤10 mIU/L.
METHODS: The presence of the conditions that should be considered for the treatment of SCH according to ATA and AACE was evaluated in 252 women who were diagnosed with SCH and had TSH levels ≤10 mIU/L. Pregnant women were excluded.
RESULTS: Antithyroperoxidase antibodies (TPOAbs) were detected in 137 (54.3%) women. A high cardiovascular risk was observed in 43 (17%) women. Eighty (31.7%) women who were not at high cardiovascular risk presented at least one classical risk factor (arterial hypertension, elevated level of low-density lipoprotein-cholesterol or low level of high-density lipoprotein-cholesterol, smoking, or first-degree family history of premature coronary artery disease). At least one symptom or sign of hypothyroidism that could not be explained by another condition was observed in 180 (71.4%) women. Two hundred thirty-two (92%) women had positive TPOAbs, or at least one classical cardiovascular risk factor, or at least one symptom or sign of hypothyroidism.
CONCLUSIONS: According to the new ATA and AACE guidelines, L-T4 therapy would be considered for 92% of women with SCH and TSH ≤10 mIU/L.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627903     DOI: 10.1089/thy.2012.0502

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  5 in total

Review 1.  Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.

Authors:  Meritxell Tost; José Antonio Monreal; Antonio Armario; Juan David Barbero; Jesús Cobo; Clemente García-Rizo; Miquel Bioque; Judith Usall; Elena Huerta-Ramos; Virginia Soria; Javier Labad
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

Review 2.  Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis.

Authors:  Martin Feller; Marieke Snel; Elisavet Moutzouri; Douglas C Bauer; Maria de Montmollin; Drahomir Aujesky; Ian Ford; Jacobijn Gussekloo; Patricia M Kearney; Simon Mooijaart; Terry Quinn; David Stott; Rudi Westendorp; Nicolas Rodondi; Olaf M Dekkers
Journal:  JAMA       Date:  2018-10-02       Impact factor: 56.272

3.  Impact of subclinical hypothyroidism with TSH ≤10 mIU/L on glomerular filtration rate in adult women without known kidney disease.

Authors:  Pedro Weslley Souza Rosario; Maria Regina Calsolari
Journal:  Endocrine       Date:  2018-01-11       Impact factor: 3.633

4.  2019 Update on Medical Overuse: A Review.

Authors:  Daniel J Morgan; Sanket S Dhruva; Eric R Coon; Scott M Wright; Deborah Korenstein
Journal:  JAMA Intern Med       Date:  2019-11-01       Impact factor: 21.873

5.  Association of thyroid peroxidase antibody and dyslipidemia in subclinical hypothyroidism.

Authors:  Vikas Kumar Srivastava; Harkaran Singh
Journal:  J Family Med Prim Care       Date:  2017 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.